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Astrocytes contribute to pathogenesis of neuropsychiatric disorders, including major
depression. Stimulation of astroglial 5-HT2B receptors transactivates epidermal growth
factor receptors (EGFRs) and regulates gene expression. Previously we reported that
expression of 5-HT2B receptors in cortical astrocytes is down-regulated in animals, which
developed anhedonia in response to chronic stress; moreover this down-regulation
as well as anhedonia, are reversed by chronic treatment with fluoxetine. In this study
we have investigated whether astrocytic 5-HT2B receptor is involved in anhedonia in
C57BL/6 mice model of Parkinson’ disease (PD) induced by intraperitoneal injection of
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) for 7 days. The MPTP treatment
induced anhendonia in 66.7% of animals. The appearance of depressive behavior
was accompanied with motor deficiency and decrease of tyrosine hydroxylase (TH)
expression. Expression of mRNA and protein of 5-HT2B receptor in animals that became
anhedonic decreased to 77.3 and 79.3% of control groups, respectively; in animals that
received MPTP but did not develop anhedonia the expression of 5-HT2B receptor did
not change. Experiments with FACS-sorted isolated cells demonstrated that decrease
in 5-HT2B receptor expression was confined to astrocytes, and did not occur in
neurons. Fluoxetine corrected MPTP-induced decrease of 5-HT2B receptor expression
and depressive behavior. Our findings indicate that regulation of gene expression of 5-
HT2B receptors in astroglia may be associated with pathophysiological evolution of PD-
induced depression.
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Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder originating from a progressive
loss of dopamine-containing neurons in the substantia nigra pars compacta (SNpc;
Hornykiewicz and Kish, 1987). Clinically, the disease is characterized by resting tremor,
slowness of movement, rigidity and postural instability (Fahn and Przedborski, 2000),
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which are often accompanied with cognitive deficits and
behavioral abnormalities. Depression is the most common
psychiatric symptom of the PD and is the major factor that
negatively impacts on the life quality (Costa et al., 2012).
Nevertheless, 5-HT seems to be the most important monoamine
related to the pathophysiology and the action of antidepressants.
5-HT deletion may also play roles in motor and non-motor
features of PD (Fox et al., 2009).
The morbid changes associated with depression affect not
only neurons; there is constantly increasing evidence that
astrocytes contribute to pathogenesis of various neuropsychiatric
disorders (Verkhratsky et al., 2014). The number of astrocytes
is significantly decreased in the brain of depressed patients
(McNally et al., 2008), whereas treatment with antidepressants
has been shown to increase expression of astrocytic markers
glial fibrillary acidic protein (GFAP) and ALDH1L1 (Barley
et al., 2009). The role of astroglia in pathogenesis of PD
remains to be fully characterized. Importantly, astrocytes
specifically express monoamine oxidase-B associated with
catabolism of catecholamines and dopamine (Ekblom et al.,
1993). Incidentally, increased astrocytic expression of MAO-B
in inducible transgenic mouse triggered Parkinsonian symptoms
(Siddiqui et al., 2011).
In clinical settings, PD-associated depression is treated
with antidepressants, including selective serotonin reuptake
inhibitors (SSRIs). Astrocytes express multiple neurotransmitter
receptors, that include 5-HT2 receptors to serotonin, and α- and
β-adrenergic receptors (Li et al., 2008a,b; Du et al., 2010; Ding
et al., 2013). Previously, we reported that a SSRI fluoxetine acts
as an agonist at 5-HT2B receptors and induces transactivation
of epidermal growth factor receptor (EGFR) in astrocytes (Li
et al., 2008b). We further discovered that expression of astrocytic,
but not neuronal 5-HT2B receptors is down-regulated in cerebral
cortex of anhedonic animals, which has been exposed to chronic
mild stress (CMS). The down-regulation of 5-HT2B receptors,
as well as anhedonia, was reversed by chronic treatment with
fluoxetine (Li et al., 2012). This finding suggests the role for
astrocytic 5-HT2B receptor in depression.
A ‘‘designer drug’’, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) is most widely used for producing
animal models of PD. The MPTP (which by itself is non-
toxic), is a lipophilic substance that crosses blood-brain barrier
and is accumulated in astrocytes, where MAO-B converts it
to the toxic metabolite, MPP+. This latter is released from
astrocytes and is transported into dopaminergic neurones by
dopamine transporter; subsequently MPP+ acts is a potent
inhibitor of mitochondrial Complex I in dopaminergic neurons,
thus compromising ATP synthesis, increasing production of
reactive oxygen species and leading to cell death (for review,
see Meredith et al., 2008). In the present study, we investigate
the relationship between gene expression of 5-HT2B receptor
and the occurrence of depressive behavior by tests such as
sucrose preference test, forced swim test, tail suspension and
open field tasks in the MPTP animal model of PD. Motor
symptoms and the tyrosine hydroxylase (TH) staining of
dopaminergic neurons are also examined in parallel with
depressive behavior.
Materials and Methods
Animals
Male C57BL/6 mice (Chang Sheng Biotechnology, Benxi, China),
weighing 22–26 g, male FVB/NTg(GFAP-GFP)14Mes/J or
B6.Cg-Tg(Thy1-YFPH)2Jrs/J mice (The Jackson Laboratory, Bar
Harbor, ME, USA), weighing 20–25 g and CD-1 mice (Charles
River, Beijing, China), weighing 30–40 g were kept at standard
housing conditions with light/dark cycle of 12 h. Water and food
were provided ad libitum. All experiments were carried out in
accordance with the USA National Institute of Health Guide for
the Care and Use of Laboratory Animals (NIH Publications No.
8023) and its 1978 revision, and all experimental protocols were
approved by the Institutional Animal Care and Use Committee
of China Medical University.
MPTP Treatment
C57BL/6 mice and FVB/NTg(GFAP-GFP)14Mes/J or B6.Cg-
Tg(Thy1-YFPH)2Jrs/J mice were daily injected intraperitoneally
with MPTP (25 mg/kg dissolved in 0.9% NaCl) or saline for
7 days. C57BL/6 mice were tested: (i) 3 days (n = 15); (ii)
7 day (n = 25); (iii) 14 day (n = 25) or (iv) 21 day after first
injection (n = 15). FVB/NTg(GFAP-GFP)14Mes/J or B6.Cg-
Tg(Thy1-YFPH)2Jrs/J mice were sacrificed 7 day (n = 9) or 14
day after first injection (n = 9).
Fluoxetine Treatment
After either 7 days or 14 days of MPTP treatment, mice with
anhedonia were daily injected intraperitoneally with fluoxetine
(10 mg/kg/d dissolved in 0.9% NaCl) or saline for 14 days.
Behavioral Testing
After lesioning, C57BL/6 mice were subjected to a series of
behavioral tests for motor activity (pole test and rotarod test),
depression behavior (sucrose preference test, forced swim, tail
suspension and open field tasks).
The pole test is a test for assessing movement disorder in mice,
and was performed as previously described (Matsuura et al.,
1997) with minor modifications. The mouse was placed head-
upward on the top of a vertical rough-surfaced pole (diameter
1 cm; height 55 cm). The time to turn downward from the top
(T-turn time) and to descend to the floor (T-LA time) were
measured. The total time was recorded with a maximum duration
of 30 s.
Rotarod is a test for assessing motor coordination in mice.
Mice were placed on a rotating bar set to a rotation speed of up to
18 rpm during the test. The time spent on the rotating bar, known
as the latent period, was recorded. Latency to fall was recorded
with a stopwatch, with a maximum of 90 s. The test subject was
immediately given two trials, and mean latencies were subject to
statistical analysis.
Tail suspension test is a despair-based test, measuring the
duration of immobility of animals subjected to inexorable
conditions. Mice were individually suspended by their tails at
the height of 20 cm using a piece of adhesive tape wrapped
around the tail 2 cm from the tip. Behavior was videotaped
for 6 min. The duration of immobility was measured by an
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observer blinded to the treatment groups. Mice were considered
immobile only when completely motionless, and mice that
climbed their tails were excluded from the data (Gorton et al.,
2010).
Forced swimming test is also a despair-based test. Mice
were dropped individually into glass cylinders (20 × 20 cm)
containing 30 cm deep water that maintained at 25 ± 1◦C
and remained for 6 min. The time of immobility was recorded
during the last 4 min of 6-min testing period, followed 2 min of
habituation.
Open field test is an anxiety based test. An open field box
(60 × 60 × 40 cm) divided in to 9 squares was used. Mice
were placed into the center square. Behaviors were videotaped
for 5 min. The parameters used for analysis included total travel
distance and time spend in the central area.
The sucrose preference test is a reward-based test and
performed as a measure of anhedonia, the lack of interest
in pleasant activities. Anhedonia is one, but not the only,
characteristic symptom of major depression (Li et al., 2012).
Baseline sucrose preference was measured before lesion. After
20 h of food and water deprivation, mice were placed in
individual cages and presented with two pre-weighted bottles,
one containing 2.5% sucrose solution and another filled with
water for 2 h. Percent preference was calculated according to
the following formula: % preference = [sucrose intake/(sucrose
+ water intake)]· 100. A decrease of sucrose preference below
65% was taken as the criterion for anhedonia. This criterion was
based on the fact that none of the control mice exhibited less than
or equal to 65% preference for sucrose at that time point of the
experiment.
Sickness behaviors were measured by body weight, line
crossing and social behavior according to the methods of
Godbout et al. (2005). Mice were maintained in their home cage
(26 × 20 cm) which was divided into six identical rectangles,
and locomotor activity was video recorded during 3 min tests.
A trained observer who was blind to experimental treatments
determined the incidence of line crossing. For social exploration,
a CD1 juvenile mouse was introduced into the test subject’s home
cage for a 5-min period. The time spent by the experimental
mouse showing exploratory behavior towards the caged juvenile
was recorded by a trained person blind to treatment. Social
behavior was determined as the amount of time that the
experimental subject spent investigating (e.g., anogenital sniffing,
trailing) the juvenile.
TH Immunohistochemistry
Mice were anesthetized with pentobarbital and perfused with
0.9% saline, followed by 4% paraformaldehyde in 0.1 M PBS.
Brains were extracted and post-fixed in 4% paraformaldehyde
overnight at 4◦C. They were transferred to a 30% sucrose
solution. The cryoprotection brains were sectioned serially at
30 µm using a cryostat microtome. Brain slices were pre-
incubated in 0.3% Triton X-100 for 30 mins. Then, sections
were incubated with mouse anti-TH antibody (1:1000) overnight
at 4◦C. After re-warming at 37◦C for 30 min, biotin labelled
goat anti-rabbit serum (the second antibody) and horseradish
peroxidise labelled streptavidin were added in turn according
to the instruction of UltraSensitiveTM SP IHC Kit (Maixin
Biotech., Fuzhou, China). The color was shown with 3,3’-
diaminobenzidine tertrahydrochloride (DAB). All sections were
air-dried, dehydrated in ascending grades of ethanol, cleaned in
xylene and fixed on coverslips with mounting media. Images
were obtained using a bright-field microscope.
Preparation of Freshly Isolated Cells
FVB/NTg(GFAP-GFP)14Mes/J or B6.Cg-Tg(Thy1-YFPH)2Jrs/J
mice express fluorescent marker under control of a cell-
specific promoter (GFAP for astrocytes or Thy1 for neurones)
thus allowing fluorescence-activated sorting of specified cell
fractions (Lovatt et al., 2007). Fluorescence-activated sorting
was performed as described previously (Wang et al., 2015).
Immediately after decapitation, cerebral hemispheres (without
olfactory bulbs and hippocampi) were removed. The remaining
parts of the brains were placed in cold Hanks buffer containing
glutamate receptor antagonists (3 µM DNQX and 100 µM
APV), cut into small pieces, and digested with 8 U/ml papain
in Ca2+/Mg2+-free PIPES/cysteine buffer, pH 7.4, for 1 h at
37◦C in a humidified atmosphere of CO2/air (5:95%). After
one wash, the tissue was further digested with 40 U/ml DNase
I in Mg2+-containing minimum essential medium (MEM)
with 1% bovine serum albumin (BSA) for 15 min at 37◦C
in a humidified atmosphere of CO2/air (5:95%). It was then
carefully triturated in cold MEM with 1% BSA, and centrifuged
over a 90% Percoll gradient, followed by collection of all
cells below and including the lipid layer. This suspension was
further diluted five times, with MEM containing 1% BSA, and
centrifuged to collect the pellet. Immediately thereafter, the
cells were re-suspended in cold MEM with 1% BSA and 4
µg/ml propidium iodide and sorted by fluorescence-activated
cell sorting (FACS) using the BD FACSAria Cell Sorting System
(35 psi sheath pressure, FACSDiva software S/W 2.2.1; BD
Biosciences, San José, CA, USA) as described by Lovatt et al.
(2007). GFP and YFP were excited by a 488 nm laser, and
emissions were collected by 530 nm discrimination filters. Cell
identity and purity were verified by mRNA expression of cell
markers of astrocytes, neurones and oligodendrocytes, analyzed
by reverse-transcription polymerase chain reaction (RT-PCR), in
astrocytic and neuronal cell preparations. As shown previously
(Fu et al., 2012) there is no contamination with neuronal
or oligodendrocytic genes in the samples of astrocytes or of
astrocytic or oligodendrocytic genes in the neuronal samples.
Since only a relatively small amount of cells is obtained, mRNA
but not protein (requiring a larger amount of cells) could be
determined.
Primary Cultures of Astrocytes
Primary cultures of mouse astrocytes were prepared from the
neopallia of the cerebral hemispheres of newborn CD-1 mice as
previously described (Hertz et al., 1978, 1998; Wang et al., 2015),
sparsely seeded, and grown in Dulbecco’s Minimum Essential
Medium (DMEM) with 7.5 mM glucose. After 2 weeks in vitro,
0.25 mM dibutyryl cyclic AMP (dBcAMP) was included in
the medium. These cultures are highly enriched in astrocytes
(>95% purity of glial fibrillary protein-(GFAP-) and glutamine
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synthetase-expressing astrocytes (Hertz et al., 1985). Addition of
dBcAMP leads to a morphological and functional differentiation
as evidenced by the extension of cell processes and increases
in several metabolic and functional activities characteristic of
astrocytes in situ (Meier et al., 1991). MPTP at 20 µM was
added to the culture after 3 weeks of culturing and for 8, 12
and 24 h.
Reverse Transcription-Polymerase Chain
Reaction (RT-PCR)
RT-PCR was performed as described previously (Wang et al.,
2015). For determination of mRNA expression of 5-HT2B
receptor by RT-PCR, all samples from cerebral cortex, freshly
isolated cells or astrocyte cultures were homogenized in Trizol.
The RNA pellet was precipitated with isopropanol, washed with
70% ethanol, and dissolved in 10 µl sterile, distilled water, and an
aliquot was used for determination of the amount of RNA (Kong
et al., 2002).
RT was initiated by a 5 min-incubation at 65◦C of 1 µg
RNA extract with Random Hexamer at a final concentration of
12.5 ng/l and deoxy-ribonucleoside triphosphates (dNTPs) at a
final concentration of 0.5 mM. The mixture was rapidly chilled
on ice and briefly spun, and 4 µl 5 × First-Strand Buffer, 2 µl
0.1 M dithiotreitol and 1 µl RNase OUT Recombinant RNase
Inhibitor (40 U/µl) were added. After the mixture had been
incubated at 42◦C for 2 min, 1 µl (200 U) of Superscript II was
added, and the incubation at 42◦C continued for another 50 min.
Subsequently the reaction was inactivated by heating to 70◦C for
15 min, and the mixture was chilled and briefly centrifuged.
Polymerase chain reaction (PCR) amplification was
performed in a Robocycler thermocycler with 0.2 µM of sense
or antisense and 0.375 U of Taq polymerase for 5-HT2B receptor
(forward; 5′ CTCGGGGGTGAATCCTCTGA 3′; reverse; 5′
CCTGCTCATCACCCTCTCTCA 3′; Kong et al., 2002), for
TATA box-binding protein (TBP), used as a housekeeping
gene (forward; CCACGGACAACTGCGTTGAT; reverse;
GGCTCATAGCTACTGAACTG; el-Marjou et al., 2000).
Initially the template was denatured by heating to 94◦C for 2
min, followed by 2.5 min amplification cycles, each consisting of
two 45-s periods and one 60-speriod, the first at 94◦C, the second
at 57◦C for 5-HT2B receptor, and at 55◦C for TBP, and the third
at 72◦C. The final step was extension at 72◦C for 10 min. The
PCR products were separated by 1% agarose gel electrophoresis,
stained with 0.5 µg/ml ethidium bromide, and captured by
Fluorchem 5500 (Alpha Innotech Corporation, San Leandro,
CA, USA). The sizes of the PCR product of 5-HT2B receptor was
370 bp and that of TBP 236 bp.
Western Blotting
Western blotting was performed as described previously (Wang
et al., 2015). Protein content was determined by the Lowry
method (Lowry et al., 1951), using BSA as the standard.
Samples containing 50 µg protein were applied on slab gels
of 10% polyacrylamide and electrophoresed. After transfer to
polyvinylidene fluoride (PVDF) membranes, the samples were
blocked by 5% skim milk powder in TBS-T (30 mM Tris-
HCl, 125 mM NaCl, 0.1% Tween 20) for 1 h. The PVDF
membranes were incubated with the first antibody, specific
to 5-HT2B receptor overnight at 4◦C or β-actin for 2 h at
room temperature. After washing, the blots were incubated
with peroxidase-conjugated affinity-purified goat-anti-rabbit or
goat-anti-mouse horseradish antibody for 2 h. Staining was
visualized by ECL detection reagents. Digital images obtained
using Gel-Imaging System (Tanon 4200, Shanghai, China).
Optical density for each band was assessed using the Window
AlphaEase TM FC 32-bit software. Ratios were determined
between scanned 5-HT2B receptor and β-actin, used for
housekeeping.
Statistics
Differences between multiple groups were evaluated by one-
way analysis of variance (ANOVA) followed by Fisher’s
least significant difference (LSD) multiple comparison test for
unequal replications. Spearman correlation was used to assess
associations between gene expression of 5-HT2B receptor and
sucrose consumption. The level of significance was set at
p< 0.05.
Materials
Most chemicals, including MPTP, BSA, DNase I, propidium
iodide, 6,7-dinitroquinoxaline-2,3-dione (DNQX), 2-amino-5-
phosphonovalerate (APV) and first antibodies, raised against
β-actin were purchased from Sigma (St. Louis, MO, USA).
Anti-TH antibody [EP1533Y] are purchased from Abcam
(Cambridge, UK) and UltraSensitiveTM SP IHC Kit from
Maixin Biotech. (Fuzhou, China). BD Biosciences (Franklin
Lakes, NJ, USA) supplied the first antibody, raised against
5-HT2B receptor. The second antibody goat anti-mouse
IgG HRP conjugate was from Promega (Madison, WI,
USA) and goat anti-rabbit IgG HRP conjugate from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). ECL detection
reagents were from Amersham Biosciences, Buckinghamshire,
UK. Random Hexamer, deoxyribonucleotide triphosphates
(dNTPs) and Taq-polymerase for RT-PCR were purchased
from TaKaRa Biotechnology Co., Ltd. (Dalian, China), and
Superscript II from Gibco Life Technology Invitrogen (Grand
Island, NY, USA). Chemicals for preparation of culturing
medium were purchased from Sigma (St. Louis, MO, USA)
and horse serum from Invitrogen (Carlsbad, CA, USA).
Flurchem 5500 was from Alpha Innotech (San Leandro,
CA, USA).
Results
Effects of MPTP on Expression of mRNA and
Protein of 5-HT2B Receptor
The time course of expression of 5-HT2B receptor mRNA
during MPTP intraperitoneal injection for 7 days is shown
on Figure 1A. At 3 days, there was no difference in 5-HT2B
receptor expression in cerebral tissues obtained from control,
saline and MPTP groups. However, after 7 days of treatment,
mRNA of 5-HT2B receptor decreased to 80.7% of control and
saline groups (n = 6, p < 0.05). It was further decreased to
77.3% after 14 days of treatment (7 days after the cessation of
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FIGURE 1 | MPTP induced down-regulation of expression of mRNA and protein of 5-HT2B receptor in brain, in astrocytes isolated by FACS from
cerebral hemispheres in vivo from mice and in astrocytes in primary cultures. (A) mRNA expression measured by RT-PCR of 5-HT2B receptor in cerebral
cortex in vivo from C57BL/6 mice treated with MPTP (25 mg/kg/d, 7 days, i.p.). A representative experiment showing mRNA for 5-HT2B receptor and for TATA
BOX-BINDING PROTEIN (TBP), as a housekeeping gene. The size of PCR product of 5-HT2B receptor is 370 bp, and that of TBP 236 bp. Similar results were
obtained in six independent experiments. Average mRNA expression was quantified as ratio between 5-HT2B receptor and the housekeeping TBP gene. Ratios
between 5-HT2B receptor and TBP in control group were designated a value of one. SEM values are indicated by vertical bars. ∗ Indicates statistically significant
(p < 0.05) difference from control and saline group at the same treatment period. (B) mRNA expression measured by RT-PCR of 5-HT2B receptor in astrocytes and
neurons isolated by FACS from cerebral hemispheres in vivo from mice (FVB/NTg(GFAP GFP)14Mes/J or B6.Cg-Tg(Thy1-YFPH)2Jrs/J) treated with MPTP
(25 mg/kg/d, 7 days, i.p.). A representative experiment showing mRNA for 5-HT2B receptor and for TBP, as a housekeeping gene. Similar results were obtained in
three independent experiments. Average mRNA expression was quantified as ratios between 5-HT2B receptor and the housekeeping TBP gene. Ratios between
5-HT2B receptor and TBP in control group were designated a value of one. SEM values are indicated by vertical bars. ∗ Indicates statistically significant (p < 0.05)
difference from other groups in the same cell type. (C) Protein expression measured by immunoblotting of 5-HT2B receptor (55 kDa) in cerebral cortex in vivo from
C57BL/6 mice treated with MPTP (25 mg/kg/d, 7 days, i.p.). Immunoblots from representative experiments. Bands of 55 and 42 kDa represent 5-HT2B receptor and
β-actin, respectively. Similar results were obtained in six independent experiments. Average protein level was quantified as ratios between 5-HT2BR and β-actin.
Ratios between 5-HT2B receptor and TBP in control group were designated a value of one. SEM values are indicated by vertical bars. ∗ Indicates statistically
significant (p < 0.05) difference from other groups at the same treatment period. (D) mRNA expression of 5-HT2BR in primary cultures of astrocytes. Cells were
treated with saline (control) or MPTP (20 µM) for 8, 12 and 24 h. Southern blot from a representative experiment. The size of 5-HT2BR is 370 bp, and TBP 236 bp.
(B) Average mRNA expression was quantitated as ratios between 5-HT2BR and TBP. S.E.M. values are indicated by vertical bars, n = 6, ∗ Indicates statistically
significant (p < 0.05) difference from other groups at the same treatment period.
MPTP treatment; n = 6, p < 0.05). At 21 days (14 days after
the end of MPTP treatment), mRNA of 5-HT2B receptor was
returned to the control level. Experiments with freshly isolated
astrocytes and neurones from transgenic mice demonstrated
that the decrease of 5-HT2B receptor mRNA expression in the
in vivo brain was confined to astrocytes and was not detected
in neurones (Figure 1B). Expression of 5-HT2B receptor protein
showed similar pattern as mRNA (Figure 1C). Expression of
5-HT2B receptors was reduced in the brains of MPTP-treated
mice to 88.2% of control after 7 days and to 79.3% of control
after 14 days (7 days after the end of MPTP treatment; n = 6,
p< 0.05), and returned to the control level after 21 days (14 days
after the end of MPTP treatment; n = 6, p < 0.05). Effects
of MPTP on gene expression of 5-HT2B receptor in cultured
astrocytes is shown on Figure 1D. At 3 and 12 h, there was
no difference in 5-HT2B receptor expression between control
Frontiers in Cellular Neuroscience | www.frontiersin.org 5 October 2015 | Volume 9 | Article 388
Zhang et al. Decrease of astroglial 5-HT2BRs in MPTP model
and MPTP groups. However, after 24 h of exposure, mRNA of
5-HT2B receptor decreased to 81.6% of control group (n = 6,
p< 0.05).
Effects of MPTP on Depression Behavior
The duration of immobility of tail suspension test and time of
immobility of forced-swimming test are presented in Figure 2.
Exposure to MPTP for 3 days had no effect on duration of
immobility (saline: 239.2 ± 23.4 s, n = 6; MPTP: 280.8 ± 10.7 s,
n = 6; p > 0.05; Figure 2A). Seven days of MPTP treatment
significantly increased the duration of immobility (saline: 236.1
± 20.8 s, n = 6; MPTP: 318.7 ± 4.2 s, n = 9; p < 0.05), and the
duration further increased after 14 days (7 days after the end of
MPTP treatment; saline: 253.9 ± 18.2 s, n = 6; MPTP: 327.3 ±
3.4 s, n = 8; p < 0.05). The duration of immobility in MPTP-
treated mice then started to decrease and was not significantly
different from control group after 21 days (14 days after the end
of MPTP treatment; saline: 249.1± 17.2 s, n = 6; MPTP: 264.1±
22.9 s, n = 6; p > 0.05).
In forced-swimming test, exposure to MPTP for 3 days
significantly increased the time of immobility (saline: 45.6 ±
11.2 s, n = 5; MPTP: 84.1 ± 9.9 s, n = 6; p < 0.05;
Figure 2B); immobility duration further increased after 7 days
(saline: 55.3 ± 9.1 s, n = 5; MPTP: 104.5 ± 6.6 s, n = 6;
p < 0.05), and reached maximum after 14 days (7 days after
the end of MPTP treatment; saline: 47.0 ± 3.4 s, n = 5;
MPTP: 135.4 ± 3.9 s, n = 6; p < 0.05). The time of
immobility in MPTP-treated mice returned to control level after
21 days (14 days after the end of MPTP treatment; saline:
60.0 ± 3.3 s, n = 5; MPTP: 62.0 ± 13.5 s, n = 6; p >
0.05).
The total distance traveled and time spend in the central in
open field test are presented in Figures 3A,B. Exposure to MPTP
for 3 days had no effect on the total distance traveled at all the
time points (Figure 3A), but decreased time spend in the central
area after 14 days (saline: 27.6± 2.9 s, n = 5; MPTP: 17.46± 1.6 s,
n = 6; p< 0.05; Figure 3B).
Changes in the consumption of sucrose, indicative of MPTP-
induced anhedonia are shown on Figure 3C. Exposure to MPTP
for 3 days had no effect on sucrose consumption (control: 82.77
± 6.61%, n = 6; saline: 79.62 ± 4.71%, n = 6; MPTP: 76.43 ±
3.61%, n = 9; p > 0.05). Seven days of MPTP treatment decreased
sucrose consumption significantly (control: 79.63 ± 8.2%, n = 6;
saline: 80.65 ± 6.75%, n = 6; MPTP: 69.34 ± 3.67%, n = 9;
p < 0.05), and it further decreased after 14 days (7 days
after the end of MPTP treatment; control: 83.41 ± 6.14%,
n = 6; saline: 78.59 ± 5.00%, n = 6; MPTP: 59.80 ± 5.00%,
n = 9; p < 0.05). The consumption of sucrose in MPTP-treated
mice returned to control level after 21 days (14 days after
the end of MPTP treatment; control: 80.39 ± 5.18%, n = 6;
saline: 80.24 ± 2.37%, n = 6; MPTP: 81.05 ± 6.79%, n = 9;
p > 0.05).
Spearman correlation analysis was carried out to determine
the relationship between gene expression of 5-HT2B receptor
mRNA and the data of behavior test. Scatter plots was made
between data of sucrose consumption and gene expression of
5-HT2B receptor mRNA (Figure 4A). From 3–21 days of MPTP
FIGURE 2 | Effects of MPTP on tail suspension test and
forced-swimming test. (A) Tail suspension test. C57BL/6 mice with or
without MPTP (25 mg/kg/d, 7 days, i.p.) were individually suspended from
their tails at the height of 20 cm using a piece of adhesive tape wrapped
around the tail 2 cm from the tip. Behavior was videotaped for 6 min. The
values are expressed as the mean ± SEM, n = 6, ∗ Indicates statistically
significant (p < 0.05) difference from other groups at the same treatment
period. (B) Forced-swimming test. C57BL/6 mice with or without MPTP
treatment (25 mg/kg/d, 7 days, i.p.) were dropped individually into glass
cylinders (10 × 10 cm) containing 10 cm deep water that maintained at
25 ± 1◦C and remained for 6 min. The time of immobility was recorded during
the last 4 min of 6-min testing period, followed 2 min of habituation. The values
are expressed as the mean ± SEM, n = 5–6, ∗ Indicates statistically significant
(p < 0.05) difference from other groups at the same treatment period.
treatment 5-HT2B receptor expression correlates positive with
sucrose consumption (p = 0.000, r = 0.727). This suggests that
there is a positive relationship between the behavior change and
receptor expression.
5-HT2B Receptor Expression in Brains
of Anhedonia Mice
Subsequently, we analyzed sucrose consumption in each MPTP-
treated mouse with average value in control group by t test.
Exposure to MPTP resulted in anhedonia in 33.3% of C57BL/6
mice (three out of nine animals) after 7 days treatment and 66.7%
(6 out of 9 animals) after 14 days, while this percentage was 50%
in CMS-treated CD-1 mice (Li et al., 2012). In non-anhedonia
animals (n = 3) exposed to MPTP sucrose consumption was
75.19 ± 3.27% or 76.19 ± 1.19% after 7 or 14 days of
treatment (p > 0.05) compared to control and saline groups),
while in anhedonia animals (n = 6) it decreased to 57.65 ±
2.35% or 51.61 ± 4.40% (p < 0.05 compared to control and
saline groups) after 7 or 14 days, respectively. Figures 4B,C
shows mRNA and protein expression of 5-HT2B receptor in
control, saline, anhedonia and non-anhedonia groups after 7
and 14 days of treatment. Gene expression of 5-HT2B receptor
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FIGURE 3 | Effects of MPTP on open field test and sucrose
consumption. (A) The total distance traveled in the central in open field test.
C57BL/6 mice with or without MPTP treatment (25 mg/kg/d, 7 days, i.p.) were
placed into the center square. Behaviors were videotaped for 5 min. The
values are expressed as the mean ± SEM, n = 5–7, ∗ Indicates statistically
significant (p < 0.05) difference from other groups at the same treatment
period. (B) The time spend in the central in open field test. C57BL/6 mice with
or without MPTP treatment (25 mg/kg/d, 7 days, i.p.) were placed into the
center square. Behaviors were videotaped for 5 min. The values are
expressed as the mean ± SEM, n = 5–7, ∗ Indicates statistically significant
(p < 0.05) difference from other groups at the same treatment period.
(C) Percentage of sucrose preference measured in C57BL/6 mice with or
without MPTP treatment (25 mg/kg/d, 7 days, i.p.). Values were expressed as
the mean ± SEM (control: n = 6; saline: n = 6; MPTP: n = 9). ∗ Indicates
statistically significant (p < 0.05) difference from other groups at the same
treatment period.
was significantly decreased in anhedonia group but not in non-
anhedonia group.
Effects of Fluoxetine on Gene Expression of
5-HT2B Receptor and Behavior Changes of
Anhedonia Mice
After either 7 days or 14 days (7 days after the end of MPTP
treatment) of MPTP treatment, mice with anhedonia were daily
injected intraperitoneally with fluoxetine (10 mg/kg/d dissolved
in 0.9% NaCl) or saline for 14 days. Exposure to MPTP for 7 days
decreased mRNA and protein expression to 80.3 and 77.3% of
control levels, respectively (n = 6, p < 0.05; Figures 5A,B). It
was further decreased to 66.8 and 67.4% after 14 days of MPTP
treatment (n = 6, p < 0.05). Chronic treatment with fluoxetine
up-regulated gene expression of 5-HT2B receptor to its normal
levels at both time points (n = 6, p< 0.05).
Fluoxetine corrected MPTP-induced decrease of sucrose
consumption (Figure 5C) and time of immobility in forced-
swimming test (Figure 5D)
Effects of MPTP on Motor Activity
On rotarod performance test, the latency of fall (Figure 6A) in
mice treated with MPTP was significantly shorter than in control
groups after 3 days (control: 86.3 ± 2.4 s; saline: 87.3 ± 1.6 s;
MPTP: 22.7 ± 5.4 s; n = 6, p < 0.05) and 7 days (control:
82.8 ± 4.4 s; saline: 78.4 ± 5.9 s; MPTP: 27.8 ± 6.1 s; n = 6,
p < 0.05) of MPTP treatment. Although the animals could stay
on the rotating rod longer after 14 days (7 days after the end
of MPTP treatment; control: 77.2 ± 7.1 s; saline: 79.3 ± 6.3 s;
MPTP: 34.9 ± 12.0 s; n = 6, p < 0.05) and 21 days (14 days after
the cease of MPTP treatment; control: 77.7 ± 7.5 s; saline: 83.7
± 3.1 s; MPTP: 48.5 ± 13.7 s; n = 6, p < 0.05), the latencies
of fall in these mice were still significantly shorter than control
groups.
Treatment with MTPT also impaired performance in the pole
test. The time taken by the mice to turn completely downward
(Figure 6B; T-turn time) was significantly increased after 3 days
(control: 2.8 ± 0.7 s; saline: 2.1 ± 0.4 s; MPTP: 15.7 ± 2.1 s;
n = 6, p < 0.05), 7 days (control: 1.9 ± 0.2 s; saline: 1.9 ± 0.3 s;
MPTP: 13.1± 1.8 s; n = 6, p< 0.05) and 14 days (7 days after the
end of MPTP treatment; control: 2.1 ± 0.5 s; saline: 2.5 ± 0.9 s;
MPTP: 12.3± 1.5 s; n = 6, p< 0.05) of the experiment. However,
after 21 days of experiment the pole test performance showed no
difference between control and MTPT-treated mice (control: 2.3
± 0.9 s; saline: 2.3 ± 0.8 s; MPTP: 2.0 ± 0.5 s; n = 6, p > 0.05).
Similar results were also observed in the time taken to reach the
floor (Figure 6C; T-LA time).
Effects of MPTP on Sickness Behaviors
Effect of MPTP on sickness behaviors is shown in Table 1.
It includes body weight, lines crossed and social exploration(s).
Only body weight showed significant decrease at 7 days (saline:
−0.75± 0.62%, n = 15; MPTP:−5.95± 1.07%, n = 26; p< 0.05)
and 14 days (7 days after the end of MPTP treatment; saline:
−0.64± 1.39%, n = 15; MPTP:−5.25± 0.99%, n = 22; p< 0.05).
MPTP had no effect on lines crossed and social exploration(s) at
all the time points examined.
Effect of MPTP on TH Expression in
Dopaminergic Neurons
Treatment with MPTP significantly decreased number of TH-
positive cells in sections of SN (Figure 7). The number of TH
cells begun to decrease after 3 days of treatment (73.3 ± 5.35%
of control group, n = 7, p < 0.05). After 7 days of treatment the
decrease in cell number reached its maximum (68.7 ± 6.44% of
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FIGURE 4 | 5-HT2B receptor expression in the brain of anhedonia mice. (A) Correlation analysis between gene expression of 5-HT2B receptor mRNA and the
data of behavior test. 5-HT2B receptor expression showed a positive correlation with sucrose consumption (p = 0.000, r = 0.727). P-values were two-tailed, and
p<0.01 was considered significant. (B) mRNA expression measured by RT-PCR of 5-HT2B receptor in cerebral cortex in vivo from anhedonia or non-anhedonia
mice. A representative experiment showing mRNA for 5-HT2B receptor and for TBP, as a housekeeping gene. The size of PCR product of 5-HT2B receptor is 370 bp,
and that of TBP 236 bp. Similar results were obtained in three independent experiments. Average mRNA expression was quantified as ratios between 5-HT2B
receptor and the housekeeping TBP gene. Ratios between 5-HT2B receptor and TBP in control group were designated a value of one. SEM values are indicated by
vertical bars. ∗ Indicates statistically significant (p < 0.05) difference from control and saline group at the same treatment period. (C) Protein level measured by
immunoblotting of 5-HT2B receptor (55 kDa) in cerebral cortex in vivo from anhedonia or non-anhedonia mice. Immunoblots from representative experiments. Bands
of 55 and 42 kDa represent 5-HT2B receptor and β-actin, respectively. Similar results were obtained in three independent experiments. Average protein level was
quantified as ratios between 5-HT2BR and β-actin. Ratios between 5-HT2B receptor and β-actin in control group were designated a value of one. SEM values are
indicated by vertical bars. ∗ Indicates statistically significant (p < 0.05) difference from other groups at the same treatment period.
control group, n = 7, p < 0.05). After 14 and 21 days treatment,
the cell number began to recover but remained significantly
lower than in control (14 days: 80.0 ± 2.75% of control group,
n = 7, p < 0.05; 21 days: 86.6 ± 3.69% of control group, n = 7,
p< 0.05).
Discussion
Depression is one of the most common non-motors symptoms
in PD, with prevalence above 50% (Pachana et al., 2013).
The pathophysiological mechanisms underlying depression in
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FIGURE 5 | Effects of fluoxetine on gene expression of 5-HT2B receptor and behavior changes of anhedonia mice. After either 7 days or 14 days (7 days
after the end of MPTP treatment) of MPTP treatment, mice with anhedonia were daily injected intraperitoneally with fluoxetine (10 mg/kg/d dissolved in 0.9% NaCl) or
saline for 14 days. (A) mRNA expression of 5-HT2B receptor was measured by RT-PCR. A representative experiment showing mRNA for 5-HT2B receptor and for
TBP, as a housekeeping gene. The size of PCR product of 5-HT2B receptor is 370 bp, and that of TBP 236 bp. Similar results were obtained in three independent
experiments. Average mRNA expression was quantified as ratios between 5-HT2B receptor and the housekeeping TBP gene. Ratios between 5-HT2B receptor and
TBP in control group were designated a value of one. SEM values are indicated by vertical bars. ∗ Indicates statistically significant (p < 0.05) difference from other
groups. (B) Protein level measured by immunoblotting of 5-HT2B receptor (55 kDa). Immunoblots from representative experiments. Bands of 55 and 42 kDa
represent 5-HT2B receptor and β-actin, respectively. Similar results were obtained in three independent experiments. Average protein level was quantified as ratios
between 5-HT2BR and β-actin. Ratios between 5-HT2B receptor and β-actin in control group were designated a value of one. SEM values are indicated by vertical
bars. ∗ Indicates statistically significant (p < 0.05) difference from other groups. (C) Percentage of sucrose preference. Values were expressed as the mean ± SEM
(7 days, n = 5; 14 days, saline: n = 6, MPTP: n = 6, flu: n = 5, MPTP plus flu: n = 6). ∗ Indicates statistically significant (p < 0.05) difference from other groups at the
same treatment period. (D) Forced-swimming test. The values of immobility time are expressed as the mean ± SEM (7 days, n = 5; 14 days, saline: n = 6, MPTP:
n = 6, flu: n = 5, MPTP plus flu: n = 6). ∗ Indicates statistically significant (p < 0.05) difference from other groups at the same treatment period.
PD are far from being clear; possibly these are related
to aberrations in serotonergic, adrenergic or dopaminergic
neurotransmission (Ossowska and Lorenc-Koci, 2013). In
clinical context, depression in PD, when compared to major
depression, exhibits high degree of dysphoria, irritability,
and pessimism about the future, with lower incidence of
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inadequacy, senses of guilt, sorrow and shame (Lieberman, 2006).
Incidentally, dopaminergic agonists demonstrate antidepressant
effect in PD patients and the recovery rate is better than after
treatment with classical antidepressant drugs (Ossowska and
Lorenc-Koci, 2013, and references therein). Rats systemically
injected with MPTP for 18 days (Kryzhanovskiı et al., 1995) as
well as in rats which received MPTP injection into substantia
nigra (Santiago et al., 2010) developed anhedonia (as measured
by sucrose consumption) very similarly to our results presented
in this paper.
To the best of our knowledge, our present work is the first
that suggests the role of astroglial 5-HT2B receptors in the
pathophysiology of depression associated with MPTP model of
PD. The 5-HT2B receptors, discovered in Foguet et al. (1992),
and classified the 5-HT2B receptors in Schmuck et al. (1994) are
expressed in various types of brain cells. First, they were found
in Purkinje neurones (Choi and Maroteaux, 1996) and later
the specific 5-HT2B receptor mRNAs was identified in freshly
isolated fractions of neurons and astrocytes from adult mice
(Li et al., 2012) in which cell-specific markers were linked with
differently fluorescent compounds thus allowing cell separation
using FACS. The relevance of 5-HT2B receptors to depression
is corroborated by (i) the decrease of its gene expression in
the nervous tissue of animals developing anhedonia under the
CMS, in non-anhedonic animals that were subjected to the same
CMS protocol expression of 5-HT2B receptors is unchanged (Li
et al., 2012); (ii) the up-regulation of 5-HT2B receptor gene
expression by chronic treatment with fluoxetine in astrocytes
in cultures and freshly isolated from the in vivo brains (Li
et al., 2009, 2012); and (iii) the dependence of antidepressant
effect of SSRIs on 5-HT2B receptors in vivo (Diaz et al., 2012).
Our present study shows that the down-regulation of gene
expression of 5-HT2B receptors occurs specifically in astrocytes
in parallel with the development of depressive behaviors in
MPTP animal model of PD. In addition, fluoxetine up-regulated
expression of 5-HT2B receptors gene in the brains of MPTP-
treated animals to the level of control group and corrected the
depression behaviors-induced by MPTP. This finding provides
another evidence that astrocytic 5-HT2B receptor is involved in
depression.
Sickness behavior is a coordinated set of adaptive behavioral
changes, including depression that develop in the course of an
infection. It has been suggested that sickness behavior is general
responses to systemic inflammation, resulting from peripheral
stimulus-induced production of cytokines in the brain (Ferrari
and Tarelli, 2011), which may complicate in the pathophysiology
of PD. In the present study, we found that MPTP treatment
significantly reduced body weight. We cannot exclude the
involvement of sickness behavior in MPTP model since in mice
MPTP treatment indeed stimulated plasma IL-1 and IL-6 (Luo
et al., 2004). However, there is no evidence that fluoxetine
effects on sickness behavior or 5-HT2B receptors are reduced by
systemic inflammatory and brain cytokines.
The mechanism(s) underlying the down-regulation of
astroglial 5-HT2B receptors upon MPTP treatment is unknown,
although its development shares the time course of extinction of
TH-positive neurons in the striatum. The down-regulation of
serotonin receptors in astrocytes may also reflect global deficit of
serotonergic system in PD. The levo-dopa is known to potentiate
serotonergic system, which is believed to be responsible for
levo-dopa-induced diskenisia, whereas sarizotan (EMD128130),
an agonist of 5-HT1A receptor, is used in clinic because of
its inhibitory effect on 5-HT release (Bibbiani et al., 2001).
The MPTP also seems to be toxic for cortical serotonin axons
(Nayyar et al., 2009), which could directly affect serotonergic
transmission. In the brains of PD patients and of MTPT-treated
primates concentration of 5-HT in the prefrontal cortex is
decreased (Scatton et al., 1983; Pérez-Otaño et al., 1991; Pifl
et al., 1991; Russ et al., 1991). In the mouse brain, MPTP
effect on 5-HT system is not consistent, probably reflecting the
differences in experimental protocols. In the acute treatment,
i.e., 4 intra-peritoneal injections of MPTP (20 mg/kg) over an
8 h period significantly decreased dopamine level in striatum
(Nayyar et al., 2009; Gorton et al., 2010; De Benedetto et al.,
2014), whereas 5-HT concentration was decreased in the
somatosensory and medial prefrontal cortex, and the density of
serotonergic axons was decreased in the medial prefrontal cortex
(Nayyar et al., 2009). In rats which received direct injection of
MPTP into substantia nigra, hippocampal reduction in 5-HT
concentration was accompanied with depression-like behaviors
TABLE 1 | Effect of MPTP on sickness behaviors (body weight changes, locomotor activity and social exploratory behavior).
0 Day 3 Days 7 Days 14 Days 21 Days
Body weight Saline – −1.11 ± 1.38 −0.75 ± 0.62 −0.64 ± 1.39 −0.67 ± 1.28
changes (%) (n = 15) (n = 15) (n = 15) (n = 18)
MPTP – −4.30 ± 1.02 −5.95 ± 1.07∗ −5.25 ± 0.99∗ −0.05 ± 1.18
(n = 13) (n = 25) (n = 22) (n = 14)
Lines crossed Saline 57.17 ± 5.18 51.50 ± 8.84 54.33 ± 7.80 57.50 ± 6.30 50.00 ± 6.13
(n = 6) (n = 6) (n = 6) (n = 6) (n = 6)
MPTP 47.00 ± 7.00 49.12 ± 5.98 52.71 ± 5.44 55.86 ± 4.91 50.86 ± 4.80
(n = 7) (n = 7) (n = 7) (n = 7) (n = 7)
Social exploration (s) Saline 147.00 ± 18.15 146.60 ± 11.27 150.00 ± 23.00 152.20 ± 8.29 171.60 ± 13.19
(n = 5) (n = 5) (n = 5) (n = 5) (n = 5)
MPTP 151.20 ± 13.38 150.67 ± 14.95 161.83 ± 18.16 139.67 ± 12.83 152.33 ± 6.56
(n = 5) (n = 6) (n = 6) (n = 6) (n = 6)
∗Significantly different from the corresponding saline group (p < 0.05).
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FIGURE 6 | Effects of MPTP on motor activity. C57BL/6 mice were
treated with MPTP (25 mg/kg/d, 7 days, i.p.). Test was done on the 3rd day,
7th day (1 day after the cease of MPTP treatment), 14th day (7 days after the
cease of MPTP treatment) and 21th day (14 days after the cease of MPTP
treatment). (A) The rotarod test. The latency to fall off the rotarod was
recorded. The values are expressed as the mean ± SEM, n = 6, ∗ Indicates
statistically significant (p < 0.05) difference from other groups at the same
treatment period. (B) T-turn time. The time taken for the mice to turn
completely downward in the pole test. The values are expressed as the mean
± SEM, n = 6, ∗ Indicates statistically significant (p < 0.05) difference from
other groups at the same treatment period. (C) T-LA time. The time taken for
the mice to reach the floor in the pole test. The values are expressed as the
mean ± SEM, n = 6, ∗ Indicates statistically significant (p < 0.05) difference
from other groups at the same treatment period.
(Santiago et al., 2010). However, in sub-acute treatment, similar
to that used in the present study, MPTP did not induce any
significant changes in 5-HT concentration in the brain (Nayyar
et al., 2009). Nevertheless, we have to keep in mind that in
all the studies mentioned above, 5-HT concentrations were
measured as total concentration in the brain homogenates
and not extracellular transmitter released from neural cells. In
addition, MPTP also decreased 5-HT2B receptors expression
in cultured astrocytes, suggesting that this phenomenon may
be only applicable to MPTP induced Parkinson’s conditions.
FIGURE 7 | MPTP induced reduction of TH expression in dopaminergic
neurons. (A) Photomicrographs of representative SN sections stained with an
antibody against TH. Scale bar = 100 µM. (B) Quantitative analysis of
TH-positive neuron numbers in the SN. The values are expressed as the mean
± SEM, n = 7. ∗ Indicates statistically significant (p < 0.05) difference from
control and saline groups. ∗∗ Indicates statistically significant (p < 0.05)
difference between control, saline and MPTP 7 days groups.
Although this hypotheses can be tested in other animal models,
such as 6-hydroxydopamine (6-OHDA), this compound also
has direct effect on astrocytes (Zhang et al., 2005). We probably
cannot make final conclusion without postmortem examination
of 5-HT2B receptors in patients’ brain.
We have studied astrocytic 5-HT2B receptor extensively in
recent years. In astrocytes 5-HT has much higher affinity to
5-HT2B receptor than to 5-HT2C receptor (Li et al., 2010).
Various SSRIs activate astroglial 5-HT2B receptors and induce
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EGFR transactivation (Zhang et al., 2010), which, in turn,
regulates expression of multiple genes (for review, see Peng and
Huang, 2012; Hertz et al., 2015). Among these genes, expression
of 5-HT2B receptor and cPLA2 are significantly reduced in mice
that become anhedonic after chronic stress, but not in those
that does not develop anhedonia (Li et al., 2012). We have
demonstrated recently that chronic treatment with fluoxetine
up-regulates these two genes in astrocytes in the brains of
anhedonic animals (Dong et al., 2015). This is in agreement
with our present findings that astrocytic 5-HT2B receptor is
decreased in mice that become anhedonic, but not in those that
does not develop anhedonia in MPTP-treated mice. Our study
suggests that astrocytic 5-HT2B receptor may be also involved in
depression associated with the PD and up-regulation of astrocytic
5-HT2B receptor expression by chronic treatment with fluoxetine
may be one the mechanism of action of antidepressants.
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